The global pharmaceutical industry is entering a structural acceleration phase of M&A, rather than a simple cyclical upswing. The core driver has shifted from periods of abundant capital and occasional mega-deals to persistent growth anxiety. 

As the patent cliff approaches in a concentrated wave, while the development cycle for innovative drugs has not significantly shortened, multinational pharmaceutical companies (MNCs) are increasingly relying on external acquisitions to fill their growth gaps.

In the context of ongoing consolidation across the global pharmaceutical industry, HongKong DengYueMed, as an international pharmaceutical supply chain and distribution partner, is also helping connect more innovative drug resources with global markets.

A clear shift can be observed in the 2025 deal structure: M&A is no longer driven by early-stage “story assets,” but instead increasingly focused on de-risked, high-certainty assets. Programs that have reached Phase IIb/III or already demonstrate commercial validation have become the primary sources of valuation premiums. This also means that rising deal values do not reflect higher risk appetite, but rather a deliberate reduction in uncertainty.

In terms of therapeutic focus, capital is becoming increasingly concentrated in a few key areas, including GLP-1 therapies, oncology bispecific antibodies, rare diseases, as well as respiratory and neurological disorders. These areas share common characteristics: well-defined clinical pathways, large addressable markets, and high predictability of commercialization. In other words, capital allocation is shifting from technology-driven bets to cash-flow visibility-driven decisions.

At the same time, platform-based assets are being re-rated. RNA platforms, antibody engineering platforms, and clinical data platforms are increasingly commanding premium valuations. As a result, M&A logic is gradually evolving from simply acquiring products to acquiring capabilities and end-to-end innovation systems.

Looking into 2026, this trend is expected to further intensify. The pressure from patent expirations is accelerating, while competition in next-generation blockbuster drugs is entering a highly competitive phase, significantly narrowing the window for successful in-house development. As a result, M&A is likely to show two key characteristics: increasing transaction volume but high concentration in top-tier assets, and sustained premium valuations with stricter selection criteria.

From a broader perspective, Chinese innovative drug assets are transitioning from a supplementary role to an increasingly important source of global deal flow. In particular, areas such as ADCs and metabolic diseases highlight China’s improving R&D efficiency, which is being globally revalued.

Overall, the key question for 2026 is no longer whether large-scale M&A will continue, but which assets will still be selected under increasingly stringent capital requirements. In other words, the industry is shifting from capital-driven M&A to asset-selection-driven M&A.

Top 10 Global Pharma M&A Deals in 2025：